Efficacy and tolerability of intravenous brivaracetam for status epilepticus: A systematic review

Moalong, Kevin Michael C.; Espiritu, Adrian I.; Fernandez, Marc Laurence L.

doi:10.1016/j.jns.2020.116799

Cited by 13 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levetiracetam and its new analogue Brivaracetam are safer, given their metabolism, poor drug interactions and lack of adverse cardio-respiratory events [ 49 , 50 ].…”

Section: Neurological Disease Manifestationsmentioning

confidence: 99%

Insights into neurological dysfunction of critically ill COVID-19 patients

Deana

Verriello

Pauletto

et al. 2021

Trends in Anaesthesia and Critical Care

View full text Add to dashboard Cite

Novel coronavirus spread rapidly around the world infecting millions of people. It was thus declared a pandemic. This new virus damages the lungs. In the most severe cases, it leads to acute respiratory failure that requires intensive care treatment. However, many clinical reports have listed different neurological symptoms, leading to increased interest in the neurological involvement of COVID-19. Various pathophysiological mechanisms have been proposed to explain these neurological aspects. Direct viral invasion of the nervous system, systemic cytokine storm and severe hypoxemia are key factors in the development of symptoms. Critically ill patients present several additional risk factors for nervous system damage. Reasons for these include deep sedation and extended muscular paralysis, bed rest for several days, and the inability to receive proper physical rehabilitation. After ICU treatment, COVID-19 patients generally require an extensive rehabilitation program. However, distancing restrictions mean that in many cases physiotherapists are unable to enter ICUs, delaying the process of rehabilitation. The role of telemedicine should be considered as an adjunctive tool in the rehabilitation of critically ill COVID-19 patients.

show abstract

“…Levetiracetam and its new analogue Brivaracetam are safer, given their metabolism, poor drug interactions and lack of adverse cardio-respiratory events [ 49 , 50 ].…”

Section: Neurological Disease Manifestationsmentioning

confidence: 99%

Insights into neurological dysfunction of critically ill COVID-19 patients

Deana

Verriello

Pauletto

et al. 2021

Trends in Anaesthesia and Critical Care

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, chemical synthesis processes generally deal with difficulties involving low yield, high cost, cumbersome steps, low product purity, and serious pollution. Since the BRV patent will expire in 2021, its market demand is increasing daily, but there are remain certain limitations in its synthesis route, which causes its current active pharmaceutical ingredient (API) market price to be extremely high 7,11 . Therefore, it is of great scientific significance and economic value to carry out the research on synthesis processes for chiral drug BRV and related substances, to develop an economical industrial process route and to increase BRV's high optical purity.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is extremely selective and reversible and can be more completely combined with the SV2A subunit; its binding force is about 15 to 30 times that of levetiracetam (LEV). It has better pharmacokinetic parameters, pharmacological properties, clinical efficacy, and safety than LEV 7,8 and shows excellent antiepileptic activity in various epilepsy models. 9 Its drug interaction risk is low, and it can be administered independently, which gives it exceptional marketing prospects; it is expected to become one of the next blockbuster drugs after LEV.…”

mentioning

confidence: 99%

“…At present, there are many reports on the synthetic route of BRV, which mainly include the chiral chromatographic column preparation, chiral enantiomer resolution, and asymmetric synthesis methods. 7,10 However, chemical synthesis processes generally deal with difficulties involving low yield, high cost, cumbersome steps, low product purity, and serious pollution. Since the BRV patent will expire in 2021, its market demand is increasing daily, but there are remain certain limitations in its synthesis route, which causes its current active pharmaceutical ingredient (API) market price to be extremely high.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A novel lipase from Aspergillus oryzae WZ007 catalyzed synthesis of brivaracetam intermediate and its enzymatic characterization

Zhang

et al. 2020

Chirality

View full text Add to dashboard Cite

Brivaracetam is a structural derivative of the chiral drug levetiracetam and has been approved for the adjuvant treatment of partial epilepsy. As a new antiepileptic drug, it is widely used in a variety of epilepsy models. In this study, a novel lipase M16 derived from Aspergillus oryzae WZ007 was cloned, expressed, and used for chiral resolution. Lipase M16 has a high enantioselectivity to the racemic substrate (R,S)-methyl 2-propylsuccinate 4-tert-butyl ester, and the intermediate (R)-2-propylsuccinic acid 4-tert-butyl ester of brivaracetam was obtained efficiently. Under optimal conditions, the enantiomeric excess of substrate was up to 99.26%, and the e.e. p was 96.23%. The conversion and apparent E value were 50.63% and 342.48, respectively. This study suggests a new biocatalytic resolution via lipase M16 for preparing the brivaracetam chiral intermediate and its potential application in the pharmaceutical industry.

show abstract